Merck Eprova and Isofol Medical Enter Exclusive Agreement for Merck Eprova’s Modufolin® in oncology
• Leucovorin has been a mainstay of colorectal cancer treatment for 50 years • Modufolin® may offer an improved profile over leucovorin in cancer therapy • New licensing deal will allow clinical trials to begin later this year Schaffhausen/ Switzerland, November 11, 2009 – Today Merck Eprova AG announced that the company has signed an …